Xilio Therapeutics (NASDAQ:XLO) reported quarterly earnings of $0.81 per share which beat the analyst consensus estimate of $(0.12) by 775 percent. This is a 128.93 percent increase over losses of $(2.80) per share from the same period last year. The company reported quarterly sales of $13.686 million which beat the analyst consensus estimate of $7.960 million by 71.93 percent. This is a 693.85 percent increase over sales of $1.724 million the same period last year.